Co.don

Co.don FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Co.don (CNWK.DE) as of Nov 10, 2026 is 72.99 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 106.04 % — a change of -31.17% (lower).

FCF Conversion

72.99 %

YoY

-31.17%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Co.don is 2020 72.99 % . FCF Conversion Rate (FCF/EBITDA) of Co.don was 2019 106.04 % . It decreases by -31.17% lower compared to the previous year.

The Co.don FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
89.52 EUR
Jan 1, 2015
149.40 EUR
Jan 1, 2016
103.73 EUR
Jan 1, 2017
141.22 EUR
Jan 1, 2018
248.56 EUR
Jan 1, 2019
106.04 EUR
Jan 1, 2020
72.99 EUR
The Co.don FCF Conversion history
YEARFCF ConversionYoY
72.99 %-31.17%
106.04 %-57.34%
248.56 %+76.00%
141.22 %+36.14%
103.73 %-30.57%
149.40 %+66.90%
89.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co.don Stock analysis

What does Co.don do? Co.don AG is a German company specializing in regenerative medicine. The company was founded in 1993 and is headquartered in Teltow near Berlin. Co.don aims to develop innovative therapies for tissue and joint damage to enable faster recovery for patients. Co.don's business model is based on the concept of tissue engineering. The company produces autologous cell therapies based on a patient's own cells. This means that the patient's own tissue is harvested to cultivate new and healthy cells that can be implanted back into the patient's body. Co.don offers various divisions to best meet the needs of patients. One of the most well-known divisions is cartilage cell therapy, which was developed to provide patients with the opportunity to heal damaged cartilage tissue in a gentle and effective manner. Another area in which the company operates is bone cell therapy. Autologous bone cells are produced to regenerate fractured or diseased bones. The company also has a division for skin-based cell therapy, which aims to heal tissue defects and minimize scarring. Co.don also offers various products tailored to the specific needs of patients. One of the most well-known products is the "Co.don Chondrosphere®" implant, made from autologous cartilage cell tissue. This implant is used to repair cartilage damage in joints and other areas of the body. Another product offered by the company is the "Co.don ViviSpray®" bone substitute material. It is produced by mixing autologous bone cells with a carrier material to promote natural bone formation. In recent years, the company has gained increasing international recognition and is now a well-known player in the field of regenerative medicine. The company has received numerous awards and has conducted several successful clinical trials that demonstrate the effectiveness of Co.don's products. Overall, Co.don AG is a company specializing in the production of autologous cell therapies. The company offers various divisions and manufactures products tailored to the specific needs of patients. With its innovative work, Co.don has contributed to revolutionizing the way tissue and joint damage are treated. Co.don is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co.don stock

FCF Conversion Rate (FCF/EBITDA) of Co.don is 72.99 % in 2020.

FCF Conversion Rate (FCF/EBITDA) of Co.don changed from 106.04 % to 72.99 %, representing a -31.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Co.don since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Co.don with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Co.don

All Key Metrics — Co.don